| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Humans | 61 | 2025 | 6794 | 1.790 |
Why?
|
| Mammaplasty | 4 | 2020 | 5 | 1.580 |
Why?
|
| PPAR alpha | 3 | 2025 | 9 | 1.350 |
Why?
|
| Free Tissue Flaps | 5 | 2016 | 7 | 1.310 |
Why?
|
| Internship and Residency | 3 | 2020 | 62 | 1.270 |
Why?
|
| Male | 34 | 2025 | 3671 | 1.200 |
Why?
|
| Lymphedema | 4 | 2016 | 5 | 1.190 |
Why?
|
| Lymph Nodes | 3 | 2020 | 9 | 1.100 |
Why?
|
| Glaucoma | 2 | 2019 | 103 | 1.070 |
Why?
|
| Female | 32 | 2025 | 4060 | 1.050 |
Why?
|
| Middle Aged | 25 | 2025 | 2108 | 0.990 |
Why?
|
| Head and Neck Neoplasms | 5 | 2024 | 13 | 0.990 |
Why?
|
| Treatment Outcome | 14 | 2021 | 500 | 0.970 |
Why?
|
| Omentum | 2 | 2016 | 2 | 0.960 |
Why?
|
| Breast Neoplasms | 2 | 2020 | 170 | 0.920 |
Why?
|
| Lipoproteins | 1 | 2025 | 7 | 0.910 |
Why?
|
| Lipolysis | 1 | 2025 | 13 | 0.900 |
Why?
|
| Triglycerides | 1 | 2025 | 58 | 0.890 |
Why?
|
| Adult | 18 | 2021 | 2113 | 0.880 |
Why?
|
| Retrospective Studies | 17 | 2024 | 681 | 0.790 |
Why?
|
| Aged | 16 | 2025 | 1539 | 0.780 |
Why?
|
| Surgical Flaps | 2 | 2015 | 7 | 0.780 |
Why?
|
| Perforator Flap | 2 | 2020 | 2 | 0.770 |
Why?
|
| Laser Coagulation | 2 | 2020 | 6 | 0.760 |
Why?
|
| Ciliary Body | 2 | 2020 | 10 | 0.760 |
Why?
|
| Mice | 13 | 2025 | 746 | 0.760 |
Why?
|
| Pelvic Bones | 1 | 2022 | 2 | 0.750 |
Why?
|
| Fractures, Bone | 1 | 2022 | 21 | 0.740 |
Why?
|
| Receptors, Opioid, mu | 2 | 2012 | 19 | 0.720 |
Why?
|
| Visual Field Tests | 2 | 2019 | 32 | 0.720 |
Why?
|
| Animals | 16 | 2025 | 1875 | 0.710 |
Why?
|
| Surgery, Plastic | 2 | 2012 | 2 | 0.710 |
Why?
|
| Tissue Adhesions | 1 | 2021 | 4 | 0.690 |
Why?
|
| Intestinal Obstruction | 1 | 2021 | 3 | 0.690 |
Why?
|
| Conservative Treatment | 1 | 2021 | 10 | 0.680 |
Why?
|
| Child | 7 | 2022 | 524 | 0.680 |
Why?
|
| Burns, Chemical | 1 | 2021 | 4 | 0.680 |
Why?
|
| Quality of Life | 2 | 2020 | 184 | 0.660 |
Why?
|
| Pediatrics | 1 | 2021 | 39 | 0.650 |
Why?
|
| Breast Cancer Lymphedema | 1 | 2020 | 1 | 0.640 |
Why?
|
| Ophthalmology | 1 | 2020 | 39 | 0.630 |
Why?
|
| Balanitis Xerotica Obliterans | 1 | 2019 | 1 | 0.630 |
Why?
|
| Follow-Up Studies | 12 | 2025 | 268 | 0.610 |
Why?
|
| Lymphatic Vessels | 2 | 2020 | 2 | 0.610 |
Why?
|
| Postoperative Complications | 6 | 2015 | 109 | 0.590 |
Why?
|
| Corneal Ulcer | 2 | 2015 | 7 | 0.580 |
Why?
|
| Laparoscopy | 2 | 2016 | 21 | 0.570 |
Why?
|
| Tomography, Optical Coherence | 1 | 2018 | 48 | 0.570 |
Why?
|
| Visual Fields | 1 | 2018 | 70 | 0.560 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2025 | 57 | 0.560 |
Why?
|
| Adolescent | 7 | 2019 | 869 | 0.550 |
Why?
|
| Eye Infections, Bacterial | 2 | 2024 | 15 | 0.520 |
Why?
|
| Antibodies, Monoclonal | 2 | 2016 | 31 | 0.500 |
Why?
|
| Mice, Inbred C57BL | 7 | 2025 | 258 | 0.500 |
Why?
|
| Liver | 4 | 2025 | 157 | 0.490 |
Why?
|
| Corneal Perforation | 1 | 2016 | 1 | 0.490 |
Why?
|
| Dry Eye Syndromes | 1 | 2016 | 2 | 0.480 |
Why?
|
| Cyclosporine | 1 | 2016 | 7 | 0.480 |
Why?
|
| Mastectomy | 2 | 2015 | 5 | 0.480 |
Why?
|
| Immunosuppressive Agents | 1 | 2016 | 31 | 0.470 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2015 | 2 | 0.470 |
Why?
|
| Fluoroquinolones | 1 | 2015 | 2 | 0.470 |
Why?
|
| Mycobacterium chelonae | 1 | 2015 | 3 | 0.470 |
Why?
|
| Azepines | 1 | 2015 | 5 | 0.470 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2015 | 6 | 0.470 |
Why?
|
| Lymphoid Tissue | 1 | 2015 | 3 | 0.460 |
Why?
|
| Diplopia | 1 | 2015 | 4 | 0.460 |
Why?
|
| Sinusitis | 1 | 2015 | 4 | 0.460 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 72 | 0.450 |
Why?
|
| Cosmetic Techniques | 2 | 2012 | 4 | 0.440 |
Why?
|
| Intestinal Absorption | 2 | 2025 | 7 | 0.440 |
Why?
|
| Conditioning, Operant | 2 | 2012 | 17 | 0.430 |
Why?
|
| Cocaine | 2 | 2012 | 22 | 0.430 |
Why?
|
| Cholesterol | 2 | 2025 | 37 | 0.420 |
Why?
|
| Aqueous Humor | 1 | 2013 | 13 | 0.410 |
Why?
|
| Clinical Competence | 2 | 2012 | 51 | 0.410 |
Why?
|
| Exfoliation Syndrome | 1 | 2013 | 12 | 0.410 |
Why?
|
| Glaucoma, Neovascular | 1 | 2013 | 7 | 0.410 |
Why?
|
| Oxygen | 1 | 2013 | 44 | 0.400 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2013 | 76 | 0.380 |
Why?
|
| Tumor Microenvironment | 4 | 2025 | 25 | 0.380 |
Why?
|
| beta-Endorphin | 1 | 2012 | 15 | 0.370 |
Why?
|
| Morphine Derivatives | 1 | 2012 | 2 | 0.370 |
Why?
|
| Spatial Behavior | 1 | 2012 | 4 | 0.370 |
Why?
|
| Arm | 2 | 2016 | 7 | 0.360 |
Why?
|
| Motor Activity | 1 | 2012 | 26 | 0.360 |
Why?
|
| Incidence | 3 | 2022 | 197 | 0.360 |
Why?
|
| Prognosis | 6 | 2019 | 220 | 0.350 |
Why?
|
| Adipose Tissue | 2 | 2010 | 69 | 0.340 |
Why?
|
| Lipectomy | 1 | 2010 | 2 | 0.330 |
Why?
|
| Knee Injuries | 1 | 2010 | 4 | 0.330 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2010 | 2 | 0.330 |
Why?
|
| Aortic Aneurysm, Abdominal | 2 | 2007 | 4 | 0.330 |
Why?
|
| United States | 5 | 2024 | 1019 | 0.330 |
Why?
|
| Anti-Bacterial Agents | 2 | 2024 | 73 | 0.320 |
Why?
|
| Severity of Illness Index | 4 | 2018 | 118 | 0.290 |
Why?
|
| Young Adult | 4 | 2021 | 567 | 0.290 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2025 | 38 | 0.280 |
Why?
|
| Balloon Occlusion | 2 | 2018 | 3 | 0.280 |
Why?
|
| Resuscitation | 2 | 2018 | 6 | 0.280 |
Why?
|
| Aorta | 2 | 2018 | 20 | 0.280 |
Why?
|
| Blood Vessel Prosthesis Implantation | 2 | 2007 | 4 | 0.280 |
Why?
|
| Hepatocytes | 2 | 2025 | 85 | 0.260 |
Why?
|
| Peritoneal Cavity | 1 | 2007 | 1 | 0.260 |
Why?
|
| Aortic Rupture | 1 | 2007 | 2 | 0.260 |
Why?
|
| Incidental Findings | 1 | 2007 | 2 | 0.260 |
Why?
|
| Membrane Proteins | 2 | 2025 | 48 | 0.260 |
Why?
|
| Morphine | 2 | 2021 | 47 | 0.260 |
Why?
|
| Visual Acuity | 2 | 2019 | 123 | 0.260 |
Why?
|
| Signal Transduction | 3 | 2024 | 246 | 0.250 |
Why?
|
| Education, Medical, Graduate | 2 | 2020 | 28 | 0.240 |
Why?
|
| Neoplasms | 2 | 2018 | 92 | 0.240 |
Why?
|
| Monitoring, Physiologic | 2 | 2016 | 16 | 0.240 |
Why?
|
| Th17 Cells | 1 | 2025 | 4 | 0.240 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 280 | 0.230 |
Why?
|
| Dietary Fats | 1 | 2025 | 19 | 0.230 |
Why?
|
| Intestinal Mucosa | 1 | 2025 | 17 | 0.230 |
Why?
|
| Orexins | 2 | 2016 | 2 | 0.230 |
Why?
|
| Social Determinants of Health | 1 | 2025 | 22 | 0.230 |
Why?
|
| Patient Compliance | 1 | 2025 | 48 | 0.230 |
Why?
|
| Lipid Droplets | 1 | 2025 | 1 | 0.230 |
Why?
|
| Ketone Bodies | 1 | 2025 | 2 | 0.230 |
Why?
|
| Lipoprotein Lipase | 1 | 2025 | 6 | 0.230 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2025 | 13 | 0.230 |
Why?
|
| Endoplasmic Reticulum | 1 | 2025 | 21 | 0.230 |
Why?
|
| Lung Neoplasms | 1 | 2025 | 45 | 0.230 |
Why?
|
| Early Detection of Cancer | 1 | 2025 | 59 | 0.220 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2024 | 5 | 0.220 |
Why?
|
| Receptor, EphB4 | 1 | 2024 | 1 | 0.220 |
Why?
|
| Ephrin-B2 | 1 | 2024 | 1 | 0.220 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 497 | 0.220 |
Why?
|
| Prospective Studies | 3 | 2025 | 331 | 0.220 |
Why?
|
| Cataract Extraction | 1 | 2024 | 16 | 0.220 |
Why?
|
| Glucocorticoids | 1 | 2024 | 65 | 0.220 |
Why?
|
| Oleic Acid | 1 | 2024 | 4 | 0.210 |
Why?
|
| Interleukin-7 | 1 | 2024 | 2 | 0.210 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2024 | 4 | 0.210 |
Why?
|
| Abdominal Wall | 2 | 2014 | 2 | 0.210 |
Why?
|
| Hernia, Abdominal | 2 | 2014 | 2 | 0.210 |
Why?
|
| Abdominal Wound Closure Techniques | 2 | 2014 | 2 | 0.210 |
Why?
|
| Herniorrhaphy | 2 | 2014 | 5 | 0.210 |
Why?
|
| Surgical Mesh | 2 | 2014 | 4 | 0.210 |
Why?
|
| Cholesterol, Dietary | 1 | 2023 | 2 | 0.210 |
Why?
|
| Enterocytes | 1 | 2023 | 2 | 0.210 |
Why?
|
| Membrane Transport Proteins | 1 | 2023 | 3 | 0.210 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2025 | 5 | 0.210 |
Why?
|
| Wearable Electronic Devices | 1 | 2023 | 3 | 0.200 |
Why?
|
| Insulin Infusion Systems | 1 | 2023 | 15 | 0.200 |
Why?
|
| Infant | 3 | 2019 | 187 | 0.200 |
Why?
|
| Child, Preschool | 3 | 2019 | 258 | 0.190 |
Why?
|
| Sclera | 2 | 2020 | 7 | 0.190 |
Why?
|
| Rejuvenation | 3 | 2012 | 4 | 0.190 |
Why?
|
| Pelvis | 1 | 2022 | 6 | 0.190 |
Why?
|
| Radiography | 1 | 2022 | 20 | 0.190 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 2022 | 1 | 0.190 |
Why?
|
| Risk Assessment | 2 | 2015 | 197 | 0.180 |
Why?
|
| Insulin | 1 | 2023 | 146 | 0.180 |
Why?
|
| Intraocular Pressure | 2 | 2020 | 127 | 0.180 |
Why?
|
| Laser Therapy | 1 | 2021 | 16 | 0.180 |
Why?
|
| Sleep Deprivation | 1 | 2021 | 2 | 0.180 |
Why?
|
| Cognition Disorders | 1 | 2021 | 19 | 0.180 |
Why?
|
| Glaucoma Drainage Implants | 1 | 2021 | 27 | 0.180 |
Why?
|
| Trabeculectomy | 1 | 2021 | 40 | 0.180 |
Why?
|
| Adhesives | 1 | 2021 | 1 | 0.170 |
Why?
|
| Hemorrhage | 2 | 2018 | 23 | 0.170 |
Why?
|
| Ophthalmic Solutions | 2 | 2024 | 18 | 0.170 |
Why?
|
| Brain | 1 | 2021 | 94 | 0.170 |
Why?
|
| Mitochondria, Heart | 1 | 2021 | 1 | 0.170 |
Why?
|
| Therapeutic Irrigation | 1 | 2021 | 3 | 0.170 |
Why?
|
| Disease Progression | 2 | 2018 | 170 | 0.160 |
Why?
|
| Biomarkers | 1 | 2021 | 214 | 0.160 |
Why?
|
| Inguinal Canal | 1 | 2020 | 2 | 0.160 |
Why?
|
| Anastomosis, Surgical | 1 | 2020 | 3 | 0.160 |
Why?
|
| Myocardial Infarction | 1 | 2021 | 46 | 0.160 |
Why?
|
| Epigastric Arteries | 1 | 2020 | 2 | 0.160 |
Why?
|
| Aftercare | 1 | 2020 | 7 | 0.160 |
Why?
|
| Biological Transport | 3 | 2025 | 22 | 0.160 |
Why?
|
| Reward | 2 | 2012 | 18 | 0.160 |
Why?
|
| Biocompatible Materials | 2 | 2010 | 7 | 0.160 |
Why?
|
| Circumcision, Male | 1 | 2019 | 1 | 0.160 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2024 | 23 | 0.160 |
Why?
|
| Europe | 1 | 2019 | 15 | 0.160 |
Why?
|
| Cell Line, Tumor | 3 | 2025 | 156 | 0.160 |
Why?
|
| Endarterectomy | 1 | 2019 | 1 | 0.160 |
Why?
|
| Peripheral Arterial Disease | 1 | 2019 | 4 | 0.150 |
Why?
|
| Mice, Knockout | 3 | 2023 | 150 | 0.150 |
Why?
|
| Cadaver | 3 | 2020 | 12 | 0.150 |
Why?
|
| Femoral Artery | 1 | 2019 | 13 | 0.150 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2019 | 28 | 0.150 |
Why?
|
| Filtering Surgery | 1 | 2019 | 6 | 0.150 |
Why?
|
| Acetamides | 2 | 2016 | 4 | 0.150 |
Why?
|
| Isoquinolines | 2 | 2016 | 9 | 0.150 |
Why?
|
| Tonometry, Ocular | 1 | 2019 | 26 | 0.150 |
Why?
|
| Endovascular Procedures | 2 | 2018 | 5 | 0.150 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2018 | 2 | 0.150 |
Why?
|
| Genetic Therapy | 1 | 2018 | 13 | 0.150 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2018 | 5 | 0.150 |
Why?
|
| Nerve Fibers | 1 | 2018 | 17 | 0.150 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 20 | 0.150 |
Why?
|
| Retinal Ganglion Cells | 1 | 2018 | 20 | 0.150 |
Why?
|
| Optic Disk | 1 | 2018 | 29 | 0.140 |
Why?
|
| Subcutaneous Fat | 1 | 2018 | 4 | 0.140 |
Why?
|
| Combined Modality Therapy | 3 | 2015 | 33 | 0.140 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2021 | 279 | 0.130 |
Why?
|
| Microsurgery | 1 | 2016 | 1 | 0.130 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2016 | 3 | 0.130 |
Why?
|
| Anatomic Landmarks | 1 | 2016 | 4 | 0.120 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2016 | 4 | 0.120 |
Why?
|
| Health Information Exchange | 1 | 2016 | 2 | 0.120 |
Why?
|
| Information Dissemination | 1 | 2016 | 16 | 0.120 |
Why?
|
| Hypothalamic Area, Lateral | 1 | 2016 | 1 | 0.120 |
Why?
|
| Locus Coeruleus | 1 | 2016 | 1 | 0.120 |
Why?
|
| Sleep, REM | 1 | 2016 | 5 | 0.120 |
Why?
|
| Ultrasonography, Doppler | 1 | 2016 | 2 | 0.120 |
Why?
|
| Rectal Neoplasms | 1 | 2016 | 3 | 0.120 |
Why?
|
| Cohort Studies | 3 | 2016 | 285 | 0.120 |
Why?
|
| Robotic Surgical Procedures | 1 | 2016 | 7 | 0.120 |
Why?
|
| Limb Salvage | 1 | 2015 | 1 | 0.120 |
Why?
|
| Muscle, Skeletal | 1 | 2016 | 75 | 0.120 |
Why?
|
| Paecilomyces | 1 | 2015 | 1 | 0.120 |
Why?
|
| Penicillium | 1 | 2015 | 1 | 0.120 |
Why?
|
| Cornea | 1 | 2015 | 13 | 0.120 |
Why?
|
| Eye Infections, Fungal | 1 | 2015 | 8 | 0.120 |
Why?
|
| Amikacin | 1 | 2015 | 3 | 0.120 |
Why?
|
| Diagnostic Errors | 1 | 2015 | 12 | 0.120 |
Why?
|
| Clarithromycin | 1 | 2015 | 7 | 0.120 |
Why?
|
| Administration, Topical | 1 | 2015 | 20 | 0.120 |
Why?
|
| Ethmoid Sinusitis | 1 | 2015 | 1 | 0.120 |
Why?
|
| Maxillary Sinusitis | 1 | 2015 | 1 | 0.120 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 84 | 0.110 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2015 | 1 | 0.110 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2015 | 1 | 0.110 |
Why?
|
| Spinal Cord Ischemia | 1 | 2015 | 1 | 0.110 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2015 | 1 | 0.110 |
Why?
|
| Recovery of Function | 1 | 2015 | 11 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 64 | 0.110 |
Why?
|
| Carcinoma | 1 | 2015 | 13 | 0.110 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 45 | 0.110 |
Why?
|
| Orexin Receptor Antagonists | 1 | 2014 | 1 | 0.110 |
Why?
|
| Orexin Receptors | 1 | 2014 | 1 | 0.110 |
Why?
|
| Basal Forebrain | 1 | 2014 | 1 | 0.110 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2014 | 4 | 0.110 |
Why?
|
| Adenosine | 1 | 2014 | 9 | 0.110 |
Why?
|
| Skin Aging | 2 | 2012 | 2 | 0.110 |
Why?
|
| Polymethyl Methacrylate | 2 | 2012 | 2 | 0.110 |
Why?
|
| Sleep | 1 | 2014 | 14 | 0.110 |
Why?
|
| Lactic Acid | 2 | 2012 | 8 | 0.110 |
Why?
|
| Collagen | 2 | 2012 | 31 | 0.110 |
Why?
|
| Narcotic Antagonists | 2 | 2012 | 29 | 0.110 |
Why?
|
| Hyaluronic Acid | 2 | 2012 | 13 | 0.110 |
Why?
|
| Behavior, Animal | 2 | 2012 | 30 | 0.110 |
Why?
|
| Prostheses and Implants | 2 | 2016 | 10 | 0.110 |
Why?
|
| Algorithms | 2 | 2012 | 83 | 0.110 |
Why?
|
| Homeostasis | 2 | 2025 | 40 | 0.110 |
Why?
|
| Mastoiditis | 1 | 2014 | 1 | 0.110 |
Why?
|
| Lateral Sinus Thrombosis | 1 | 2014 | 1 | 0.110 |
Why?
|
| Otitis Media | 1 | 2014 | 9 | 0.110 |
Why?
|
| Intestines | 2 | 2025 | 7 | 0.110 |
Why?
|
| Contrast Media | 2 | 2011 | 18 | 0.100 |
Why?
|
| Wakefulness | 3 | 2021 | 5 | 0.100 |
Why?
|
| Fatty Acids | 2 | 2024 | 25 | 0.100 |
Why?
|
| Licensure, Medical | 1 | 2012 | 2 | 0.090 |
Why?
|
| Naltrexone | 1 | 2012 | 16 | 0.090 |
Why?
|
| Interviews as Topic | 1 | 2012 | 77 | 0.090 |
Why?
|
| Cellulose | 1 | 2012 | 1 | 0.090 |
Why?
|
| Mannitol | 1 | 2012 | 1 | 0.090 |
Why?
|
| Neuromuscular Agents | 1 | 2012 | 3 | 0.090 |
Why?
|
| Injections, Intramuscular | 1 | 2012 | 6 | 0.090 |
Why?
|
| Neurotransmitter Agents | 1 | 2012 | 5 | 0.090 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2012 | 7 | 0.090 |
Why?
|
| Appendectomy | 1 | 2011 | 13 | 0.090 |
Why?
|
| Appendicitis | 1 | 2011 | 15 | 0.090 |
Why?
|
| Time Factors | 4 | 2019 | 321 | 0.080 |
Why?
|
| Esthetics | 1 | 2010 | 1 | 0.080 |
Why?
|
| Barium Sulfate | 1 | 2010 | 2 | 0.080 |
Why?
|
| Wound Healing | 1 | 2010 | 14 | 0.080 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2010 | 11 | 0.080 |
Why?
|
| Alagille Syndrome | 1 | 2010 | 1 | 0.080 |
Why?
|
| Fractures, Spontaneous | 1 | 2010 | 4 | 0.080 |
Why?
|
| Angiography | 1 | 2010 | 15 | 0.080 |
Why?
|
| Patient Selection | 1 | 2010 | 40 | 0.080 |
Why?
|
| Lower Extremity | 1 | 2010 | 7 | 0.080 |
Why?
|
| Leadership | 1 | 2010 | 22 | 0.080 |
Why?
|
| Granuloma, Foreign-Body | 1 | 2010 | 1 | 0.080 |
Why?
|
| Program Evaluation | 1 | 2010 | 46 | 0.080 |
Why?
|
| Biofilms | 1 | 2010 | 3 | 0.080 |
Why?
|
| Soft Tissue Infections | 1 | 2010 | 7 | 0.080 |
Why?
|
| Myocardial Reperfusion Injury | 2 | 2021 | 2 | 0.080 |
Why?
|
| Connective Tissue | 1 | 2009 | 1 | 0.080 |
Why?
|
| Dermatologic Agents | 1 | 2009 | 2 | 0.080 |
Why?
|
| Injections | 1 | 2009 | 20 | 0.080 |
Why?
|
| Chyle | 1 | 2009 | 1 | 0.080 |
Why?
|
| Fistula | 1 | 2009 | 2 | 0.080 |
Why?
|
| Thoracic Duct | 1 | 2009 | 2 | 0.080 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2009 | 8 | 0.080 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2009 | 3 | 0.070 |
Why?
|
| Vascular Surgical Procedures | 1 | 2009 | 7 | 0.070 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2009 | 11 | 0.070 |
Why?
|
| Heart Diseases | 1 | 2009 | 9 | 0.070 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 104 | 0.070 |
Why?
|
| Anesthetics, Local | 1 | 2007 | 6 | 0.070 |
Why?
|
| Cholangitis | 1 | 2007 | 4 | 0.070 |
Why?
|
| Receptors, Opioid | 1 | 2007 | 25 | 0.070 |
Why?
|
| Retroperitoneal Space | 1 | 2007 | 1 | 0.070 |
Why?
|
| Risk Factors | 3 | 2019 | 767 | 0.070 |
Why?
|
| Interleukins | 1 | 2025 | 8 | 0.060 |
Why?
|
| Ribosome Inactivating Proteins, Type 1 | 2 | 2016 | 2 | 0.060 |
Why?
|
| Cell Membrane | 1 | 2025 | 54 | 0.060 |
Why?
|
| Pyridines | 2 | 2016 | 24 | 0.060 |
Why?
|
| Trust | 1 | 2025 | 33 | 0.060 |
Why?
|
| Lipid Metabolism | 1 | 2025 | 33 | 0.060 |
Why?
|
| Mitochondria | 1 | 2025 | 37 | 0.060 |
Why?
|
| Calcium | 1 | 2025 | 117 | 0.060 |
Why?
|
| Injections, Intraocular | 1 | 2024 | 1 | 0.060 |
Why?
|
| Triamcinolone Acetonide | 1 | 2024 | 2 | 0.060 |
Why?
|
| Conjunctiva | 1 | 2024 | 9 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2025 | 16 | 0.060 |
Why?
|
| Transplantation, Autologous | 2 | 2018 | 5 | 0.060 |
Why?
|
| Costs and Cost Analysis | 1 | 2024 | 16 | 0.060 |
Why?
|
| Drug Costs | 1 | 2024 | 11 | 0.060 |
Why?
|
| Anterior Chamber | 1 | 2024 | 11 | 0.060 |
Why?
|
| Endophthalmitis | 1 | 2024 | 10 | 0.060 |
Why?
|
| Neoplasm Metastasis | 1 | 2024 | 22 | 0.060 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2024 | 15 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2016 | 282 | 0.050 |
Why?
|
| Logistic Models | 2 | 2016 | 165 | 0.050 |
Why?
|
| Fenofibrate | 1 | 2024 | 2 | 0.050 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2025 | 41 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 42 | 0.050 |
Why?
|
| Rats | 2 | 2016 | 571 | 0.050 |
Why?
|
| Jejunum | 1 | 2023 | 3 | 0.050 |
Why?
|
| Liver X Receptors | 1 | 2023 | 3 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2025 | 100 | 0.050 |
Why?
|
| Phantoms, Imaging | 1 | 2023 | 2 | 0.050 |
Why?
|
| Radiation Dosage | 1 | 2023 | 8 | 0.050 |
Why?
|
| Radiation Exposure | 1 | 2023 | 6 | 0.050 |
Why?
|
| Equipment Design | 1 | 2023 | 20 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2024 | 231 | 0.050 |
Why?
|
| Obesity | 1 | 2025 | 226 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2016 | 63 | 0.050 |
Why?
|
| Intestine, Small | 1 | 2022 | 8 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2022 | 6 | 0.050 |
Why?
|
| Parenteral Nutrition | 1 | 2022 | 8 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 155 | 0.050 |
Why?
|
| Ligation | 2 | 2014 | 14 | 0.050 |
Why?
|
| Survival Rate | 2 | 2016 | 111 | 0.050 |
Why?
|
| Consciousness | 1 | 2021 | 1 | 0.050 |
Why?
|
| Nerve Net | 1 | 2021 | 3 | 0.050 |
Why?
|
| Behavior | 1 | 2021 | 3 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2021 | 11 | 0.040 |
Why?
|
| Cerebral Cortex | 1 | 2021 | 15 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2023 | 165 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2022 | 167 | 0.040 |
Why?
|
| Pandemics | 1 | 2021 | 87 | 0.040 |
Why?
|
| Myocytes, Cardiac | 1 | 2021 | 23 | 0.040 |
Why?
|
| Myocardium | 1 | 2021 | 25 | 0.040 |
Why?
|
| Epithelium | 1 | 2020 | 22 | 0.040 |
Why?
|
| Vascular Patency | 1 | 2019 | 5 | 0.040 |
Why?
|
| Constriction, Pathologic | 1 | 2019 | 9 | 0.040 |
Why?
|
| HLA-A2 Antigen | 1 | 2018 | 2 | 0.040 |
Why?
|
| Drugs, Investigational | 1 | 2018 | 2 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2018 | 7 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 59 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2018 | 13 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 54 | 0.040 |
Why?
|
| Injury Severity Score | 1 | 2018 | 7 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2018 | 234 | 0.030 |
Why?
|
| Fascia | 1 | 2016 | 3 | 0.030 |
Why?
|
| Thigh | 1 | 2016 | 4 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2016 | 20 | 0.030 |
Why?
|
| Histamine | 1 | 2016 | 1 | 0.030 |
Why?
|
| GABA-A Receptor Agonists | 1 | 2016 | 1 | 0.030 |
Why?
|
| Telemetry | 1 | 2016 | 2 | 0.030 |
Why?
|
| Norepinephrine | 1 | 2016 | 10 | 0.030 |
Why?
|
| Electromyography | 1 | 2016 | 20 | 0.030 |
Why?
|
| Electroencephalography | 1 | 2016 | 17 | 0.030 |
Why?
|
| Regional Blood Flow | 1 | 2016 | 17 | 0.030 |
Why?
|
| Reoperation | 1 | 2016 | 17 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 42 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2016 | 26 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2016 | 44 | 0.030 |
Why?
|
| Graft Survival | 1 | 2016 | 36 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 98 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2015 | 19 | 0.030 |
Why?
|
| Keratoplasty, Penetrating | 1 | 2015 | 6 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 2015 | 9 | 0.030 |
Why?
|
| Thoracic Wall | 1 | 2015 | 1 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 4 | 0.030 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2015 | 3 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 13 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 24 | 0.030 |
Why?
|
| Cholinergic Neurons | 1 | 2014 | 1 | 0.030 |
Why?
|
| Synaptic Transmission | 1 | 2014 | 4 | 0.030 |
Why?
|
| Butyric Acid | 1 | 2014 | 2 | 0.030 |
Why?
|
| Glutamic Acid | 1 | 2014 | 5 | 0.030 |
Why?
|
| Neuropeptides | 1 | 2014 | 6 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2014 | 11 | 0.030 |
Why?
|
| Craniotomy | 1 | 2014 | 1 | 0.030 |
Why?
|
| Middle Ear Ventilation | 1 | 2014 | 2 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2014 | 2 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2014 | 13 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2014 | 14 | 0.030 |
Why?
|
| Fasciotomy | 1 | 2013 | 1 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2013 | 16 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2014 | 199 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 169 | 0.020 |
Why?
|
| Iohexol | 1 | 2011 | 1 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 11 | 0.020 |
Why?
|
| Sex Factors | 1 | 2011 | 155 | 0.020 |
Why?
|
| Health Surveys | 1 | 2010 | 75 | 0.020 |
Why?
|
| Bone Cements | 1 | 2009 | 1 | 0.020 |
Why?
|
| Polyesters | 1 | 2009 | 1 | 0.020 |
Why?
|
| Durapatite | 1 | 2009 | 1 | 0.020 |
Why?
|
| Silicone Gels | 1 | 2009 | 1 | 0.020 |
Why?
|
| Face | 1 | 2009 | 4 | 0.020 |
Why?
|
| Age Factors | 1 | 2010 | 193 | 0.020 |
Why?
|
| Polymers | 1 | 2009 | 7 | 0.020 |
Why?
|
| Subclavian Steal Syndrome | 1 | 2009 | 1 | 0.020 |
Why?
|
| Thoracic Neoplasms | 1 | 2009 | 3 | 0.020 |
Why?
|
| Tracheostomy | 1 | 2009 | 4 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2009 | 8 | 0.020 |
Why?
|
| Exercise Test | 1 | 2009 | 9 | 0.020 |
Why?
|
| Benzimidazoles | 1 | 2007 | 4 | 0.020 |
Why?
|
| Piperidines | 1 | 2007 | 7 | 0.020 |
Why?
|
| Sphincterotomy, Endoscopic | 1 | 2007 | 1 | 0.020 |
Why?
|
| Decompression, Surgical | 1 | 2007 | 4 | 0.020 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2007 | 8 | 0.020 |
Why?
|
| ROC Curve | 1 | 2007 | 28 | 0.020 |
Why?
|
| Acute Disease | 1 | 2007 | 91 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2007 | 95 | 0.020 |
Why?
|
| Length of Stay | 1 | 2007 | 53 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2007 | 127 | 0.020 |
Why?
|